Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer.

导出 OA

翻译打印收藏纠错

第一作者： David E,Gerber

第一单位： Department of Internal Medicine (Division of Hematology-Oncology), USA; Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, USA. Electronic address: david.gerber@utsouthwestern.edu.

作者： David E,Gerber ^[1] ; David A,Boothman ^[2] ; Farjana J,Fattah ^[3] ; Ying,Dong ^[3] ; Hong,Zhu ^[4] ; Rachel A,Skelton ^[3] ; Laurin L,Priddy ^[3] ; Peggy,Vo ^[3] ; Jonathan E,Dowell ^[5] ; Venetia,Sarode ^[6] ; Richard,Leff ^[7] ; Claudia,Meek ^[7] ; Yang,Xie ^[4] ; Joan H,Schiller ^[5]

作者单位： Department of Internal Medicine (Division of Hematology-Oncology), USA; Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, USA. Electronic address: david.gerber@utsouthwestern.edu. ^[1] Department of Pharmacology, USA; Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, USA. ^[2] Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, USA. ^[3] Department of Clinical Sciences (Biostatistics), USA; Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, USA. ^[4] Department of Internal Medicine (Division of Hematology-Oncology), USA; Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, USA. ^[5] Department of Pathology, USA. ^[6] Texas Tech University Health Sciences Center School of Pharmacy, USA. ^[7]

关键词 Clinical trial Epidermal growth factor receptor Epigenetics Erlotinib Histone deacetylase inhibitor Non-small cell lung cancer Romidepsin